I'm LongbridgeAI, I can summarize articles.William Blair upgraded Pyxis Oncology to Outperform from Market Perform.
Recent analyst actions on Pyxis Oncology
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 20 | HC Wainwright & Co. | Reiterates | Buy | $8 |
| Nov 6 | RBC Capital | Maintains | Outperform | $7 |
| Nov 6 | Wedbush | Maintains | Outperform | $7 |
Across the three most recent analyst notes published on Pyxis Oncology over the past 30 days, price targets range from $7 to $8.
Explore more price target data and ratings for Pyxis Oncology on the , and track all previous and future analyst recommendations in the dedicated News Flow.
Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.
